AGENUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.86 USD | +3.43% |
|
+3.53% | -34.41% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 206M | Sales 2025 * | 183M | Capitalization | 228M |
|---|---|---|---|---|---|
| Net income 2024 * | -175M | Net income 2025 * | -223M | EV / Sales 2024 * | 1.11 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.24 x |
| P/E ratio 2024 * |
-1.22
x | P/E ratio 2025 * |
-1.25
x | Employees | 389 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Agenus Inc.
More recommendations
More press releases
| 1 day | +3.43% | ||
| 1 week | +3.53% | ||
| Current month | -10.40% | ||
| 1 month | +101.11% | ||
| 3 months | -17.11% | ||
| 6 months | -21.30% | ||
| Current year | -34.41% |
1 week
10.05
11.43
1 month
4.9014.24
Current year
4.7818.98
1 year
4.7842.60
3 years
4.78135.80
5 years
4.78135.80
10 years
4.78203.20
| Managers | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director of Finance/CFO | 58 | 95-12-31 | |
Craig Winter
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director/Board Member | 66 | 16-05-16 | |
Susan Hirsch
BRD | Director/Board Member | 71 | 20-10-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.15% | 25 M€ | -1.43% | - | |
| 0.01% | 746 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 10.86 | +3.43% | 430,354 |
| 24-05-16 | 10.5 | -2.60% | 405,544 |
| 24-05-15 | 10.78 | +0.75% | 356,062 |
| 24-05-14 | 10.7 | -3.52% | 399,122 |
| 24-05-13 | 11.09 | +5.72% | 395,205 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.86
USD
Average target price
44.25
USD
Spread / Average Target
+307.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.41% | 228M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +28.31% | 12.16B | |
| +24.73% | 12.17B |
- Stock Market
- Equities
- AGEN Stock
